New hope for rare liver disease: experimental drug CS0159 enters Mid-Stage trial

NCT ID NCT05896137

Ongoing Disease control Sponsor: Cascade Pharmaceuticals, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests an experimental drug called CS0159 in 50 people with primary sclerosing cholangitis (PSC), a rare liver disease. The study has a 12-week placebo-controlled phase followed by a 40-week open-label period to check safety and how well the drug works. Researchers will measure side effects and changes in liver enzyme levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CS0159 (oral drug)
What this could lead to: If successful, this could point toward a new treatment to control primary sclerosing cholangitis and reduce liver damage.
What could go wrong: This is an early Phase 2 trial with only 50 participants, so results may not apply broadly. The drug may not improve outcomes or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cholangitis, Sclerosing primary sclerosing cholangitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY SCLEROSING CHOLANGITIS

Contacts and locations

Locations

Beijing Friendship Hospital, Captail Medcial University

Beijing, Beijing Municipality, 100050, China
Beijing YouAn Hostital, Captial Medical University

Beijing, Beijing Municipality, 100069, China
Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China
Qilu Hospital of Shandong University

Jinan, Shandong, China
Renji Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, 200120, China
Shaoyifu Hospital of Zhejiang University Medical

Hangzhou, Zhejiang, 310000, China
The First Affiliated Hospital of USTC Anhui Provincial Hospital

Hefei, Anhui, China
The First Affiliated Hospital,Zhejiang University School of Medicine

Hangzhou, Zhejiang, China
The First Bethune Hospital of Jilin University

Changchun, Jilin, China
The Seconed Xiangya Hospital of Central South University

Changsha, Hunan, 410011, China
Wuhan Union Hospital of China

Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.